1      0


AM23-MN-26-O - AM23-MN-26-O: ASHI/AABB Joint Session: The Problem with Platelets: How Perspectives of Various Practitioners Involved in Platelet Support of Refractory Patients Has Led to Continuing Controversies (Enduring)


Expiration Date: Dec 31, 2025


Credits: None available.

In this session, we will demonstrate how various practitioners caring for the same immune refractory patient can have widely different practices regarding platelet support for the patient. We will show how this can lead to delays in treatment, less than effective treatment for the patient, and a waste of a scarce resource. We will propose current best practices and better communication among the practitioners involved. Additionally, we will introduce Platelet Refractory Evaluation Workgroup, which has been formed to outline the perceptions, expectations, limitations, and efficacy of managing platelet refractory patients.


Learning Objectives:

  • Explain the perspectives of the hematologist ordering platelets, the transfusion service issuing the platelet product, HLA laboratory performing HLA antibody testing and the blood collection center providing platelets
  • List the tests available that provide appropriate information leading to selection of the best platelet products for transfusion
  • Describe the testing used to monitor platelet effectiveness
  • Describe algorithms that utilize HLA testing to select the optimal platelet products for platelet immune refractory patients

Moderator(s):

Speaker(s):

Disclosures

  • Sharon Adams:
    No financial relationships to disclose
  • Patricia Kopko, MD:
    No financial relationships to disclose
  • Lesley Kresie, MD:
    No financial relationships to disclose
  • Sandhya Panch, MD MPH:
    Sanofi: Consultant/Advisory Board (Ongoing); Sobi: Speaker's Bureau (Ongoing)
  • Harold Sullivan, MD:
    Werfen/Instrumentation Laboratory: Consultant/Advisory Board (Ongoing)
  • Ralph Vassallo, MD:
    Fresenius Kabi: Consultant/Advisory Board (Ongoing); Hemanext: Consultant/Advisory Board (Ongoing); ITL: Consultant/Advisory Board (Ongoing); Terumo BCT: Speaker's Bureau (Terminated, December 14, 2021)

All relevant financial relationships have been mitigated.

By completing the evaluation, you are attesting to watching the presentation in its entirety. A certificate will be immediately provided after submission.

Credits Available


AM23-MN-26-O: ASHI/AABB Joint Session: The Problem with Platelets: How Perspectives of Various Practitioners Involved in Platelet Support of Refractory Patients Has Led to Continuing Controversies (Enduring) Evaluation